(Press-News.org) (Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy.
The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The COMPEL study is a global, randomized, double-blind trial, in which adult patients with non-CNS progression on first-line osimertinib were randomized 1:1 to receive either osimertinib 80 mg once daily or placebo once daily in combination with platinum-pemetrexed chemotherapy (cisplatin 75 mg/m2 or carboplatin AUC5 + pemetrexed 500 mg/m2 every 3 weeks for 4 cycles), followed by osimertinib 80 mg once daily or placebo once daily in combination with maintenance pemetrexed (500 mg/m2 every 3 weeks) until disease progression or another discontinuation criterion was met.
The study showed that continuing osimertinib with the addition of platinum-pemetrexed chemotherapy was associated with improved progression-free survival (PFS) compared with placebo plus chemotherapy (HR: 0.43; 95% CI: 0.27–0.70); median PFS was 8.4 months with osimertinib plus chemotherapy vs. 4.4 months with placebo plus chemotherapy. Median overall survival (OS) was also longer with osimertinib plus chemotherapy (15.9 months) vs. placebo plus chemotherapy (9.8 months) (HR: 0.71; 95% CI: 0.42–1.23).
“These results indicate that resistance to first-line osimertinib may be heterogeneous, and some tumor cells remain sensitive to continued therapy,” said lead investigator Dr. Giulia Pasello of the Veneto Institute of Oncology IOV-IRCCS in Italy. “This trial supports osimertinib as a backbone treatment strategy in this setting.”
Dr. Pasello reported that the safety and tolerability profile of the combination therapy was manageable and consistent with the known safety profiles of osimertinib and chemotherapy agents. The findings also align with results from the FLAURA2 study, which showed a benefit for first-line osimertinib combined with chemotherapy.
These results may help inform treatment decisions and emphasize the importance of personalized strategies for patients with EGFRm advanced NSCLC following progression on targeted therapy, said Dr. Pasello.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.
END
COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC
2025-09-06
ELSE PRESS RELEASES FROM THIS DATE:
CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease.
These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The study assessed HRQoL by nodal status and surgical outcomes using patient-reported outcome (PRO) measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual ...
Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.
The study, conducted by the University of Illinois Hospital & Clinics, (UI Health), the academic health enterprise of the University of Illinois Chicago (UIC), highlights Sybil’s strong performance in a real-world clinical setting with racially and socioeconomically ...
New medication lowered hard-to-control high blood pressure in people with chronic kidney disease
2025-09-06
Research Highlights:
Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have uncontrolled high blood pressure.
The analysis also found that baxdrostat lowered the loss of albumin in the urine, which is a marker of kidney and cardiovascular risk, by 55% compared to placebo, suggesting that this medication may help delay the progression of kidney disease .
These findings suggest the potential for baxdrostat to improve longer-term health outcomes like kidney and ...
Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment
2025-09-05
The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively infect and destroy tumor cells, while simultaneously stimulating anti-tumor immune responses. The latest advancements in genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced patient quality of life.
By combining OVs with cellular immunotherapy, immune checkpoint inhibitors, cancer vaccines, cytokines, and bi- or tri-specific T cell engagers, researchers have developed innovative ...
New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment
2025-09-05
Head and neck cancer remains a major global health challenge, ranking among the six most common cancers worldwide and claiming hundreds of thousands of lives each year. A growing body of evidence now points to an intricate connection between energy metabolism and immune regulation as a driving force behind the onset, progression, and treatment resistance of these cancers. The latest comprehensive review on this topic underscores the potential of targeting these intertwined processes to unlock more effective therapies.
Tumor cells in head and neck cancer exhibit profound metabolic reprogramming, altering the way they process glucose, lipids, and ...
Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor
2025-09-05
BATON ROUGE – Pennington Biomedical Research Center is proud to announce that Dr. Steven B. Heymsfield, Professor of Metabolism and Body Composition, has been named a Boyd Professor of Louisiana State University – the highest faculty rank and honor awarded within the LSU System.
The Boyd Professorship is reserved for faculty whose outstanding achievements and international reputations bring significant prestige to LSU. Dr. Heymsfield joins an elite group of scholars recognized for advancing knowledge and transforming ...
Study prompts new theory of human-machine communication
2025-09-05
Hed: Study prompts new theory of human-machine communication
LAWRENCE – In a new paper, two University of Kansas scholars propose a novel theory of communication analysis that takes into better account how people interact with ubiquitous technology in the 21st-century workplace.
In “Socio-Technical Exchange with Machines: Worker Experiences with Complex Work Technologies,” ----- link to https://doi.org/10.30658/hmc.10.3 ----------- in the Human-Machine Communications ...
New method calculates rate of gene expression to understand cell fate
2025-09-05
UNIVERSITY PARK, Pa. — Essentially all cells in an organism’s body have the same genetic blueprint, or genome, but the set of genes that are actively expressed at any given time in a cell determines what type of cell it will be and its function. How rapidly gene expression in a single cell changes over time can provide insight into how cells might become more specialized, but current measurement approaches are limited. A new method developed by researchers at Penn State and Yale University incorporates spatial information from the cell as well as data from cells processed at different times, improving researchers’ ability to understand the nuances of gene expression ...
Researchers quantify rate of essential evolutionary process in the ocean
2025-09-05
The movement of genetic material between organisms that aren’t directly related is a significant driver of evolution, especially among single-celled organisms like bacteria and archaea. A team led by researchers at Bigelow Laboratory for Ocean Sciences have now estimated that an average cell line acquires and retains roughly 13 percent of its genes every million years via this process of lateral gene transfer. That equates to about 250 genes swapped per liter of seawater every day.
The new study, recently published in The ISME Journal, provides the first quantitative analysis of gene transfer rates across an entire microbiome. It calls into question the strict classification ...
Innovation Crossroads companies join forces, awarded U.S. Air Force contract
2025-09-05
The U.S. Air Force awarded startup SkyNano, led by Innovation Crossroads alumna Anna Douglas, a $1.25 million contract to advance its CO2-to-carbon nanotube technology as part of a project to develop low-cost, battery-grade graphite. SkyNano’s partners include American Energy Technologies Company and Eonix, led by Innovation Crossroads alumnus Don DeRosa.
SkyNano and Eonix were recruited to Knoxville through Innovation Crossroads, a Lab-Embedded Entrepreneurship Program node at Oak Ridge National Laboratory.
“In addition to accessing ...